Peter Andrew Bates

Broker Network Holdings Ltd. operates a network of insurance brokers. It offers business support services such as marketing, human resources, legal, and information technology. The company was founded on February 16, 1994 and is headquartered in Knaresborough, the United Kingdom.

NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom.

Ellis Bates Financial Solutions Ltd. provides financial intermediary services. The private company is based in Harrogate, UK and has subsidiaries in the United Kingdom. The British company was founded by Paul Grant Ellis and Peter Andrew Bates. Michael Charles Cope has been the CEO of the company since 2008.